close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Diabetes Therapies & Diagnostics: Global Markets

  • Published: June 2010
  • |
  • Report Code: HLC029C

REPORT HIGHLIGHTS

  • The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
  • Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR). 
  • Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.

SUMMARY FIGURE
DIABETES MARKET EVOLUTION BY PRODUCT GROUP, 2010 AND 2015
($ BILLIONS)
DIABETES MARKET EVOLUTION BY PRODUCT GROUP, 2010 AND 2015
To Contact us, click here  help


Source: BCC Research

Download Free Chapter

REPORT SCOPE

INTRODUCTION 

STUDY GOALS AND OBJECTIVES
 
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs used in the treatment of diabetes and devices and instruments used for diagnosis and monitoring of diabetes. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2015; these are based on epidemiological data and projections, plus information on R&D trends and differential market potential on a country-by-country basis. Healthcare policies, demographics, and the wider economic environment are also taken into account.
 
REASONS FOR DOING THE STUDY
 
It is widely recognized that the prevalence of the commonest type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 DM are also on the increase, although to a less spectacular degree. These trends are of great concern, not only to the individuals concerned, but to governments and providers of healthcare, because the economic consequences of diabetes are vast, as they involve not only the direct burden of managing the disease but also the common and often catastrophic complications including cardiovascular disease, peripheral neuropathy and blindness.
 
Thus the prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and healthcare agencies. One consequence is that the already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and devices needed for monitoring.
 
Among the information needs of companies in this field is accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next 5 years, and the impact of drugs and technical developments now in the pipeline.
 
SCOPE OF REPORT
 
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, both in global terms and analyzed by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
 
MARKET ANALYSIS AND FORECASTS
 
Market figures are based on revenues at the manufacturer level and are projected at 2010-dollar value without attempting to predict the effect of inflation/deflation.
 
Therapeutic categories quantified and forecast include insulins and oral hypoglycemic agents, and devices including blood glucose monitors and accessories.
 
METHODOLOGY
 
Primary research includes interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consist of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC.
 
INTENDED AUDIENCE
 
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
 
INFORMATION SOURCES
 
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from healthcare institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
 
ANALYST CREDENTIALS
 
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects. 
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:  
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.

Download Free Chapter

REPORT TOC

download table of contents
Pricing on the website is provided for single users and 2-5 users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at (+1)781-489-7301 or send an email to information@bccresearch.com
  Title/Chapter Name Pages Price
Diabetes Therapies & Diagnostics: Global Markets 150 $3990
Chapter- 1: INTRODUCTION - Complimentary 4 $0
  Show Details
Chapter- 2: SUMMARY 2 $250
  Show Details
Chapter- 3: OVERVIEW 6 $239
  Show Details
Chapter- 4: ABOUT DIABETES 22 $878
  Show Details
Chapter- 5: DIABETES THERAPIES 21 $838
  Show Details
Chapter- 6: ORAL HYPOGLYCEMIC DRUGS 5 $200
  Show Details
Chapter- 7: DIAGNOSIS AND MONITORING 29 $1157
  Show Details
Chapter- 8: THE DIABETES MARKET 17 $678
  Show Details
Chapter- 9: NEW APPROACHES TO THE MANAGEMENT OF DIABETES 6 $239
  Show Details
Chapter- 10: COMPANY PROFILES 31 $1237
  Show Details
Chapter- 11: APPENDIX 7 $279
  Show Details
 
  List of Tables
  List of Figures
 
Select License type:

Original Price $6650
Offer Price $3990

buy now
download free chapter
Want to find out more
about this report?
request more info
Get Notified
on all the latest research reports
Subscribe

Choose your License

loading animation for AJAX calls